Sorrento Therapeutics, Inc. products

COVID-19

Antigen Test for the Detection of SARS-CoV-2 Virus in Nasal Swab

SIMPLE: 3-step test procedure. RAPID: Produces Results in 15 minutes or less. CONVENIENT: Nasal swab with simple 3 step instructions and visible read. ACCURATE: Highly sensitive platinum colloid-based lateral flow N-Antigen immunoassay to detect SARS-CoV-2 virus (Detects Omicron and Omicron Subvariants)

Immunotherapy

G-MAB Technology

Sorrento’s proprietary G-MAB technology, invented by Dr. Ji, is based on the use of RNA transcription for amplification of the antibody variable domains from over 600 donors. In-depth analysis of deep sequencing DNA data showed that the G-MAB library contains more than 10 quadrillion (10¹⁶) distinct antibody sequences. This makes it one of the largest fully human antibody libraries in the biopharmaceutical industry. Thus far, Sorrento has successfully identified fully human antibodies against over 100 clinically-relevant high-impact oncogenic targets, including PD-1, PD-L1, CD38, CD123, CD47, VEGFR2, and CCR2.

Dimeric Antigen Receptor-T Cell

Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and antigen is knocked into its locus. The Dimeric Antigen Receptor (DAR) utilizes a Fab instead of the scFv used by traditional Chimeric Antigen Receptor (CAR) T cells. We believe this DAR has been demonstrated in preclinical studies greater specificity, stability and potency.

Pain

RTX

RTX (resiniferatoxin) is a unique neural intervention molecule that is highly selective and may be applied peripherally (e.g., nerve block, intra-articular) or centrally (e.g., epidural), to control chronic pain across multiple conditions including arthritis and cancer. RTX has the potential to be a first-in-class drug addressing currently intractable pain in a novel and unique way, by targeting the nerves responsible for the chronic debilitating pain signal transmission. RTX strongly binds to TRPV1 receptors and forces open calcium channels located in the end-terminal of the nerve or the soma of the neuron (depending upon the route of administration). This in turn generates a slow and sustained cation influx that rapidly leads to the deletion of TRPV1-positive cells. RTX directly interacts with afferent nerve cells without affecting sensations such as touch, pressure, acute prickling pain, vibration sense or muscle coordination function.